Home | Welcome to Contract Pharma   
Last Updated Saturday, September 20 2014

Topics - Drug Development

Refine by Date:
From: To:
Published September 16, 2014
Gains exclusive rights to develop and commercialize products globally Read More »
Published September 16, 2014
To co-develop and commercialize BACE inhibitor, AZD3293 Read More »
Published September 12, 2014
Will leverage Evotec's high-throughput screening and proteomics platforms Read More »
Published September 12, 2014
Aims to meet clinical development needs for all therapeutic areas Read More »
Published September 11, 2014
Additional funding to support Phase II trial of CLT-008 in AML Read More »
Published September 11, 2014
Will use MabVax platform to develop anti-cancer therapeutics Read More »
Published September 10, 2014
Genmab to pay $11 million for exclusive rights to Seattle Genetics' ADC technology Read More »
Published September 8, 2014
Therapeutic antibodies target autoimmune disease Read More »
Published September 4, 2014
Calico to build a new R&D facility in the San Francisco Bay Area Read More »
Published September 3, 2014
Will focus efforts on diabetes prevention and treatment Read More »
Published August 29, 2014
PODRAS platform technology aims to prevent overdose Read More »
Published August 28, 2014
Initiates Phase II trial of AVP-786 in major depressive disorder Read More »
Published August 26, 2014
Recipharm Venture Fund invests $1.15 million in Isofol Read More »
Published August 25, 2014
Phase 1/2 trial to evaluate ADXS-PSA and pembrolizumab in prostate cancer Read More »
Published August 25, 2014
Expands respiratory portfolio globally Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On